|
|
| | AUNP-12 Basic information |
| Product Name: | AUNP-12 | | Synonyms: | AUNP-12;AUR 012;Aurigene-012;AURIGENE-012;AUR 012;L-α-Glutamine, N2,N6-bis(L-seryl-L-asparaginyl-L-threonyl-L-seryl-L-α-glutamyl-L-seryl-L-phenylalanyl)-L-lysyl-L-phenylalanyl-L-arginyl-L-valyl-L-threonyl-L-glutaminyl-L-leucyl-L-alanyl-L-prolyl-L-lysyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-lysyl-;Aurigene NP-12;NP-12 TFA;AUNP-12, PD-1 pathway inhibitor | | CAS: | 1353563-85-5 | | MF: | C142H226N40O48 | | MW: | 3261.56 | | EINECS: | | | Product Categories: | | | Mol File: | 1353563-85-5.mol |  |
| | AUNP-12 Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Water: Soluble | | form | A solid | | color | White to off-white |
| | AUNP-12 Usage And Synthesis |
| Uses | AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1]. | | Biological Activity | AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a novel immune checkpoint modulator, is an inhibitor of PD-1 signaling pathway. | | in vitro | In hPDL2-expressing HEK293 cells, AUNP-12 inhibited the binding of PD1 to PDL2 with EC50 of 0.72 nM; in hPDL1-expressing MDA-MB231 cells, in PBMC proliferation assay, EC50 was 0.41 nM. | | target | | Target | Value | PD-L1
(Cell-free assay) |
| | References | [1] Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. DOI:10.1158/1535-7163.MCT-18-0737 |
| | AUNP-12 Preparation Products And Raw materials |
|